பால் சோய் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Why Vir Biotechnology Stock Is Sinking This Week
fool.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fool.com Daily Mail and Mail on Sunday newspapers.
PBUG Maker Krafton Shares Drop By 20% after $3 8B IPO
coinspeaker.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from coinspeaker.com Daily Mail and Mail on Sunday newspapers.
Operator
Ladies and gentlemen, thank you for standing by, and welcome. [Operator Instructions]. Following the presentation, there will be a question-and-answer session. [Operator Instructions]
I would now like to hand the conference over to Ben Church, Investor Relations and Corporate Communications at Esperion. Please go ahead, sir.
Benjamin Church
Head, Corporate Communications & Investor Relations
Thank you, operator. Good morning and welcome to Esperion s Second Quarter 2021 Financial Results and Company Update Conference Call. I m Ben Church and I m responsible for Investor Relations and Corporate Communications here at Esperion.
I want to remind callers that the information discussed on the call today is covered under the Safe Harbor provisions of the Private Securities Litigation Reform Act. I caution listeners that management will be making forward-looking statements.
Operator
Greetings, and welcome to Global Blood Therapeutics conference call. [Operator instructions] As a reminder, this conference is being recorded. I would now like to turn the call over to Steven Immergut. Please go ahead, sir.
Steven Immergut
Investor Relations
Thank you, and welcome to GBT s conference call to discuss the company s financial results for the second-quarter 2021 and to provide a business update. I m Steven Immergut, head of communications and investor relations. Joining me on the call are Dr. Ted Love, our president and CEO, will provide an update on our progress in the second quarter; Jeff Farrow, our chief financial officer, will review our financial results; David Johnson, or DJ, our chief commercial officer, will give an update on the Oxbryta launch; Dr.
Operator
Good day, everyone, and welcome to Myovant Sciences first-quarter of fiscal year 2021 earnings conference call. Today s call is being recorded. At this time, I would like to turn the call over to Ryan Crowe, vice president of investor relations at Myovant. Please go ahead.
Ryan Crowe
Vice President of Investor Relations
Thank you, operator. Good morning and thanks for joining us today to review the financial results of Myovant s first quarter of fiscal year 2021 and to discuss other corporate and business updates. Joining me for today s call are Dave Marek, Myovant s chief executive officer; Frank Karbe, president and chief financial officer; Lauren Merendino, chief commercial officer; and Dr. Juan Camilo Arjona, chief medical officer.
vimarsana © 2020. All Rights Reserved.